MAIA reports 88% disease control rate in expanded Phase 2 THIO-101 lung cancer trialNov 17Clinical readoutMaia Biotechnology
Regeneron registry update: new MUC16 trial added; HS, MASH, ALD, melanoma, obesity studies continueNov 12Weekly roundup, 6 itemsALN-CIDEBALN-HSDUpdated
Regeneron-linked TOP2201 posts results; NeoSTOP-IT terminated, DEUTERON completedNov 5Weekly roundup, 7 itemsafliberceptALN-CIDEBUpdated
Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosisOct 30Weekly roundup, 6 itemscemiplimab-rwlcdupilumabUpdated
Biohaven's Q3 update: FDA accepts Vyglxia filing, SK Biopharmaceuticals deal pendingOct 29Quarterly updateBiohaven Ltd.
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Regeneron: AcTED results posted; new REGN9220 and glaucoma trials registeredOct 23Weekly roundup, 4 itemsafliberceptcemiplimab-rwlcUpdated
Regeneron week: AERIFY-1 COPD results posted; new cenvacibart, alirocumab, cemiplimab trials filedOct 16Weekly roundup, 6 itemsalirocumabcemiplimab-rwlcUpdated
Regeneron registers two new cemiplimab trials in skin cancer and early lung cancerSep 9Weekly roundup, 2 itemscemiplimab-rwlcRegeneron Pharmaceuticals
Biohaven advances degrader and epilepsy pipelines, reports Q2 2026 resultsAug 10Quarterly updateBHV-1300Biohaven Ltd.
Regeneron registers Phase 1 REGN17235 trial and joins Maryland-led lung cancer studyAug 7Weekly roundup, 2 itemscemiplimab-rwlcRegeneron Pharmaceuticals
Immuneering reports Q2 2026 results, MAPKeeper 301 dosing underwayAug 5Quarterly updateImmuneering Corporation
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab
Regeneron backs two new trials: cemiplimab in transplant patients, blood cancer genetics studyJul 20Weekly roundup, 2 itemscemiplimab-rwlcRegeneron Pharmaceuticals